Navigation Links
Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
Date:6/24/2013

>

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma.


'/>"/>
SOURCE Intercept Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Piedmont Pharmaceuticals Gains FDA Approval of Animal Health Soft Chew Pain Medication
2. North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017
3. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
4. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
5. Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer
6. GW Pharmaceuticals plc Reports 2013 Second Quarter Financial Results
7. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
8. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
9. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
10. Vanda Pharmaceuticals Reports First Quarter 2013 Results
11. Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Nuvilex, Inc. (OTCQB: NVLX) – According ... worldwide are living with diabetes, with  that number expected ... global market for diabetes treatments is approximately $500 billion.  ... died from pancreatic cancer.  Pancreatic cancer is the fourth ... the United States , and according ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... SALT LAKE CITY, March 17 Axial Biotech, ... of molecular diagnostics,and motion preserving technologies, announced today ... its development of the first genetic,prognostic test for ... million tranche of its Series B financing. The ...
... Declares Preferred Stock Dividend -, SAN DIEGO, Calif., ... ) today announced that its board of directors has,declared ... of common stock,an 8.1% increase over the company,s previous ... equivalent to an annualized dividend,of $1.34 per common share., ...
... IRVINE, Calif., March 14 Masimo Corporation,(Nasdaq: MASI ), ... pulse oximetry, today announced that it is scheduled,to present at ... The Four Seasons Hotel in Las Vegas, NV on Wednesday, ... and CEO, and Mark P. de,Raad, Executive Vice President and ...
Cached Biology Technology:Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing 2BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend 2Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference 2
(Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
(Date:10/16/2014)... have a new synthesis of recent research findings to ... in the two states. , The Ecology and ... Washington: A Synthesis of the Relevant Biophysical Science and ... published by the U.S. Forest Service,s Pacific Northwest Research ... managers for a synthesis of the large body of ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... sea ice in the Arctic has shrunk to its ... 30 years ago, opening up the Northwest Passage ... has been historically impassable. In the mosaic image ... September 2007 by the Advanced Synthetic Aperture Radar (ASAR) ...
... 2007 American Society for Microbiology (ASM) sanofi-aventis U.S. ... M.D., Ph.D., Chief, Laboratory of Malaria and Vector ... Bethesda, Maryland. Supported by an unrestricted grant ... in antimicrobial chemotherapy. Dr. Wellems has had ...
... and volunteers who helped in the clean-up effort after ... of Spain exhibit prolonged respiratory symptoms resulting from their ... to examine the long-term effects of such exposures on ... reported in the second issue for September of the ...
Cached Biology News:Satellites witness lowest Arctic ice coverage in history 2Prolonged respiratory problems for oil spill clean-up volunteers 2Prolonged respiratory problems for oil spill clean-up volunteers 3
Reacts with the 80 kDa fragment of the M-chain of human merosin....
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: